Opinion

Over the three days of Advanced Therapies Week (ATW) 2023 in Miami, Florida, US, from 18 to 20 January, DDW’s Megan Thomas heard from attendees about what they were most looking forward to learning from the event, as well as why they think the potential of cell and gene therapies outweighs the obstacles that must […]

Dr Julie Warner is Vice President of Regulatory Affairs at global drug development consultancy, Boyds. In this article, she provides her expert insights into the key regulatory developments likely to shape the global drug development industry this year.    Implementation of the EU Clinical Trials Regulation  The way clinical trials (CTs) are conducted in the European […]

By DDW Editor Reece Armstrong The looming threat of global warming, consequences of which can already be seen and felt across the planet, will impact us all. It seems that despite a constant barrage of warnings by scientists and experts, alongside visible effects such as wildfires, droughts, and blistering heatwaves, we still aren’t doing enough […]

In January 2022, DDW’s Megan Thomas spoke to decision-makers from the drug discovery industry about their predictions on what 2022 holds for our sector. As we head into 2023, DDW will be publishing a series of reflections on these predictions. Here, Thomas reflects specifically on Anita Cooper’s prediction relating to the importance of clinical trials.  […]

Social media started gaining traction in the early 2000s and has been growing steadily but DDW’s Megan Thomas has observed that it seems to have recently expanded into the world of business and significantly, the wider scientific industries. Here, she unpacks some of the areas in which social media plays a role in the drug […]

Optibrium, a developer of software and artificial intelligence (AI) solutions for drug discovery, recently announced the promotion of Dr Tamsin Mansley to President of its new subsidiary to lead its US-based team and business operations. DDW’s Megan Thomas spoke with Dr Mansley to learn more about what she considers the role of AI in drug […]

Dr Andrew Garrett, Executive Vice President of Scientific Operations at ICON, explores the benefits of integrating some of the validation and standardisation practices already developed for PIs into the practices around NPIs and public health data; outlines some of the practices that can be implemented in order to do this; and highlights the need for […]

In the Summer 2022 issue of DDW, Jessica Woodgate and Molly Edwards from life sciences recruitment company SciPro shared with DDW their ambition to champion female leaders across drug discovery through the founding of the Women in Discovery round table. Since then, the women-only environment has flourished but in the most recent instalment, men were […]

Listen to this article on the DDW Podcast: Jeff Willis, MD, PhD is a Senior Medical Director and retina specialist at Genentech. He talks to Lu Rahman about some of the company’s work developing medicine for eye disease and offers insight into the ophthalmology field today. Genentech is committed to advancing science and developing effective and […]